Journal articleJ Gastrointest Oncol2021
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report.
- Journal
- J Gastrointest Oncol
- Published
- 1 December 2021
- Citations
- 2
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 5
- Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer K08CA218420↗
- Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma P50CA127003↗
- Altered metabolism and machine learning for pancreatic cancer early detection U01CA210171↗
- Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens U01CA224146↗
- Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived canc… U01CA250549↗